April 29, 2020 / 12:48 PM / a month ago

BRIEF-AzurRx Biopharma Receives Approval To Conduct Its Phase 2 Option 2 Clinical Trial Of MS1819 In Cystic Fibrosis Therapeutics Development Network Sites

April 29 (Reuters) - AzurRx BioPharma Inc:

* AZURRX BIOPHARMA RECEIVES APPROVAL TO CONDUCT ITS PHASE 2 OPTION 2 CLINICAL TRIAL OF MS1819 IN CYSTIC FIBROSIS THERAPEUTICS DEVELOPMENT NETWORK SITES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below